PATENT CLAIM ANALYSIS

Application Number: 15926118
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "085200"]

Abstract:
Methods of modulating immune responses in subjects having oncology- and immune-related diseases, disorders and conditions by the administration of an IL-10 agent, including pegylated IL-10.

Claim (Index 110):
The method of  claim 109 , wherein the tumor antigen is selected from the group consisting of CD19, CD20, CD22, ROR1, mesothelin, CD33/IL3Ra, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, NY-ESO-1 TCR, MAGE A3 TCR, or any combination thereof.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 90.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15543949', '15751134', '15914717', '14779929', '15513825']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.745154763235145
- 35 USC 102 Novelty (BERT): 0.547524293357846
- Combined Prediction Score: 0.725391716247415
- Mean Citation Score: 247.528164
- Max Citation Score: 252.41656
- Similarity Product: 146.43864186825274

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test